Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

104.08 -1.88 (-1.77%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
54 55 Next >
3 Stocks to Buy Right Now That Are Cash Cows
If cash is king, these three stocks should wear crowns. 
Via The Motley Fool
GSK/Pfizer-Backed ViiV Healthcare's HIV Treatment At Par With Gilead's: Study Shows
Via Benzinga
Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV
From Gilead Sciences, Inc.
Via Business Wire
Kite Completes Acquisition of Tmunity
From Gilead Sciences, Inc.
Via Business Wire
If You Invested $100 In This Stock 20 Years Ago, You Would Have $2,100 Today
Via Benzinga
Elliott Wave Technical Analysis: Gilead Inc.
Looking for a clear three wave move in wave (ii) to then place longs. 
Via Talk Markets
This Recession-Proof Company Has a Best-in-Class Dividend
Pfizer's highly attractive valuation, rock-solid dividend program, and enormous yield put it at the top of its big pharma peer group. 
Via The Motley Fool
Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients
From Gilead Sciences, Inc.
Via Business Wire
Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies
From Gilead Sciences, Inc.
Via Business Wire
Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer
From Gilead Sciences, Inc.
Via Business Wire
Choroidal Neovascularization Market Share Size Trends Overview Analysis 2022-2029
Global Choroidal Neovascularization Market to Witness Huge Growth by Key Players: Bausch Health Companies Inc, Bayer AG, Gilead Sciences Inc, F.Hoffmann –La Roche AG,MaaT Pharma Novartis AG, Pfizer... 
Via SBWire
Cholecystitis Treatment Market Demand Trends Outlook Overview Analysis 2022-2029
Global Cholecystitis Treatment Market to Witness Huge Growth by Key Players: Boston Scientific, Dornier MedTech GmbH, Fresenius Kabi, AuroMedics Pharmaceuticals, Sanofi, SUNUET Pharmaceuticals, Hetero... 
Via SBWire
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
From Gilead Sciences, Inc.
Via Business Wire
Lattice Semiconductor To Rally 33%? Here Are 10 Other Analyst Forecasts For Tuesday
Goldman Sachs boosted the price target for Kaiser Aluminum Corporation (NASDAQ: KALU) from $70 to $80. Goldman Sachs analyst Emily Chieng maintained a Sell rating on the stock. Kaiser Aluminum shares... 
Via Benzinga
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends. 
Via Talk Markets
ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood
Why does Wall Street hate Cathie Wood and her ARKK ETF? Seven words show how her focus on innovation divides investors. 
Via InvestorPlace
Europe Liver Cancer Therapeutics Market to Reach at High CAGR of 8.95% by 2023-2030
The Europe liver cancer therapeutics size was valued at US$ 384 million in 2022 and is estimated to reach US$ 627 million by 2030, growing at a CAGR of 8.95% during the forecast period (2023-2030) 
Via SBWire
Kite's Tecartus CAR T-Cell Therapy Demonstrates Durable Overall Survival Benefit In Leukemia Settings
Kite, a Gilead Sciences Inc (NASDAQ: GILD) company, announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel).  
Via Benzinga
2 Biotech Stocks That Could Make You Richer
Patience will pay off with these two stocks. 
Via The Motley Fool
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
From Gilead Sciences, Inc.
Via Business Wire
Thoughts For Thursday: Risk-off, Risk-on
The one foot forward, one foot backward action continues on Wall Street, though yesterday it was more like three or four steps backward. It seems Q1 earnings jitters are responsible. 
Via Talk Markets
NeurAxis: Should You Buy This IPO?
As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype. 
Via Talk Markets
Europe Liver Cancer Therapeutics Market Is at the Cusp of Crossing CAGR of 8.95% N 2023-2030
Global Europe Liver Cancer Therapeutics Market to Witness Huge Growth by Key Players: Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead... 
Via SBWire
Topics Death
Exposures Death
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio. 
Via Talk Markets
Is Gilead Sciences a Good Stock to Buy Now?
Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward. 
Via The Motley Fool
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
Gilead Sciences' Trovelvy Scores FDA Approval For Advanced/Metastatic Breast Cancer Setting
Via Benzinga
'Risk Of Overheating': 4 Experts On Hot January Jobs Report, How The Fed Will React
The SPDR S&P 500 ETF Trust (NYSE: SPY) traded lower Friday after the Labor Department reported blowout U.S. jobs market numbers from January. 
Via Benzinga
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
54 55 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.